Retatrutide

Retatrutide is a first-in-class triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. This tri-hormonal mechanism distinguishes it from earlier mono- and dual-agonists and positions it at the frontier of metabolic peptide research, where investigators seek to understand the combined downstream effects of all three incretin and counterregulatory axes.

The glucagon component adds a hepatic dimension absent from GLP-1/GIP co-agonists, making retatrutide a particularly valuable probe for studying liver lipid oxidation, hepatic glucose output, and adipose mobilisation pathways. Research programmes have used it to map the interplay between energy intake signals (GLP-1, GIP) and energy expenditure signals (glucagon), advancing systems-level models of whole-body metabolic regulation.

Retatrutide's potent receptor engagement and long half-life — achieved through a C18 fatty-acid modification enabling albumin binding — provide stable pharmacokinetics well-suited to chronic dosing study designs. It represents an important benchmark for evaluating how incremental receptor polypharmacology affects metabolic outcomes in preclinical and translational research.

For research purposes only. Not for human consumption.